Free Trial

Absci (ABSI) Competitors

$4.82
+0.31 (+6.87%)
(As of 11:35 AM ET)

ABSI vs. TCRX, HARP, ORIC, NRC, OABI, MXCT, STRO, TNYA, LUNA, and NOTV

Should you be buying Absci stock or one of its competitors? The main competitors of Absci include TScan Therapeutics (TCRX), Harpoon Therapeutics (HARP), ORIC Pharmaceuticals (ORIC), National Research (NRC), OmniAb (OABI), MaxCyte (MXCT), Sutro Biopharma (STRO), Tenaya Therapeutics (TNYA), Luna Innovations (LUNA), and Inotiv (NOTV).

Absci vs.

TScan Therapeutics (NASDAQ:TCRX) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment, community ranking and analyst recommendations.

In the previous week, Absci had 1 more articles in the media than TScan Therapeutics. MarketBeat recorded 2 mentions for Absci and 1 mentions for TScan Therapeutics. Absci's average media sentiment score of 1.89 beat TScan Therapeutics' score of 1.77 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
TScan Therapeutics Very Positive
Absci Very Positive

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Absci shares are held by institutional investors. 2.8% of TScan Therapeutics shares are held by insiders. Comparatively, 9.8% of Absci shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TScan Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 41.01%. Absci has a consensus price target of $9.25, indicating a potential upside of 105.10%. Given TScan Therapeutics' higher possible upside, analysts clearly believe Absci is more favorable than TScan Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TScan Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Absci
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

TScan Therapeutics received 2 more outperform votes than Absci when rated by MarketBeat users. Likewise, 75.00% of users gave TScan Therapeutics an outperform vote while only 53.66% of users gave Absci an outperform vote.

CompanyUnderperformOutperform
TScan TherapeuticsOutperform Votes
24
75.00%
Underperform Votes
8
25.00%
AbsciOutperform Votes
22
53.66%
Underperform Votes
19
46.34%

TScan Therapeutics has a net margin of -653.50% compared to TScan Therapeutics' net margin of -2,042.01%. TScan Therapeutics' return on equity of -44.60% beat Absci's return on equity.

Company Net Margins Return on Equity Return on Assets
TScan Therapeutics-653.50% -61.13% -34.53%
Absci -2,042.01%-44.60%-37.58%

TScan Therapeutics has higher revenue and earnings than Absci. TScan Therapeutics is trading at a lower price-to-earnings ratio than Absci, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TScan Therapeutics$21.05M21.37-$89.22M-$1.28-6.65
Absci$5.72M89.16-$110.57M-$1.16-3.89

TScan Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500.

Summary

TScan Therapeutics beats Absci on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABSI vs. The Competition

MetricAbsciCommercial physical research IndustryMedical SectorNASDAQ Exchange
Market Cap$509.99M$5.25B$5.15B$8.26B
Dividend YieldN/A1.28%5.26%4.05%
P/E Ratio-3.8917.13120.5814.11
Price / Sales89.1675.712,337.0775.80
Price / CashN/A28.0933.7130.80
Price / Book2.373.984.904.27
Net Income-$110.57M$139.94M$109.40M$215.78M
7 Day Performance-2.38%-2.10%-0.74%-0.99%
1 Month Performance-8.15%18.82%0.47%0.33%
1 Year Performance170.06%-12.93%2.91%3.78%

Absci Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRX
TScan Therapeutics
1.9189 of 5 stars
$8.64
-0.2%
$12.00
+38.9%
+192.4%$456.71M$21.05M-6.75154Short Interest ↑
HARP
Harpoon Therapeutics
0.9343 of 5 stars
$23.01
flat
$27.25
+18.4%
N/A$389.61M$37.34M-2.6353
ORIC
ORIC Pharmaceuticals
2.945 of 5 stars
$8.89
-0.4%
$20.00
+125.0%
+55.5%$599.36MN/A-4.94102Gap Up
NRC
National Research
0.5435 of 5 stars
$26.36
-1.8%
N/A-42.7%$629.48M$148.58M21.26435
OABI
OmniAb
2.0669 of 5 stars
$4.64
+0.4%
$9.00
+94.0%
-0.9%$545.71M$34.16M-7.25106Gap Up
MXCT
MaxCyte
2.8378 of 5 stars
$4.88
+1.0%
$8.67
+77.6%
+2.9%$509.47M$41.29M-13.94143Insider Buying
News Coverage
Positive News
STRO
Sutro Biopharma
4.609 of 5 stars
$3.77
+0.3%
$12.50
+231.6%
-28.3%$308.35M$153.73M-2.01300Positive News
TNYA
Tenaya Therapeutics
2.6605 of 5 stars
$3.57
-2.7%
$15.00
+320.2%
-48.2%$280.32MN/A-2.18140Analyst Forecast
Analyst Revision
LUNA
Luna Innovations
0.992 of 5 stars
$3.62
+3.1%
$10.00
+176.2%
-62.2%$122.94M$109.50M-45.25337Upcoming Earnings
Gap Up
NOTV
Inotiv
1.4882 of 5 stars
$1.75
+2.0%
$6.19
+254.6%
-67.3%$45.32M$572.42M-0.632,055Gap Up

Related Companies and Tools

This page (NASDAQ:ABSI) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners